Home

Current Issue

Archives

Guidelines for Authors

Classified Ads

Links

Search PubMed

Subscriptions

Subscriber Registration

Guidelines for Website Users

JRheum Update Service

Contact Info

JEAN-YVES REGINSTER, OLIVIER BRUYERE, and YVES HENROTIN

ABSTRACT.

Several entities have been carefully investigated for the symptomatic and structural management of osteoarthritis (OA). The most compelling evidence of a potential for inhibiting the structural progression of OA has been obtained with glucosamine sulfate, while some preliminary results also suggest that other compounds could be used in the same indication. At any rate, several medications have clearly demonstrated a symptomatic action, mainly in OA of the lower limbs, including pain relief and improvement of functional disability. An important issue is that all conclusive studies with such chemical entities resulted from the use of prescription medicines and not over-the-counter or nutriceutical supplements. (J Rheumatol 2003;30 Suppl 67:14-20)

Key Indexing Terms:

OSTEOARTHRITIS
STRUCTURE MODIFICATION
STRONTIUM RANELATE
GLUCOSAMINE SULFATE
CHONDROITIN SULFATE
DIACEREIN
TREATMENT

J.Y. Reginster, MD, PhD, Professor of Epidemiology and Public Health, University of Liège, Director, WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases; O. Bruyere, MD, Assistant, Department of Epidemiology and Public Health, University of Liège, WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases; Y. Henrotin, MD, Department of Epidemiology and Public Health, University of Liège.

Address reprint requests to Dr. J-Y. Reginster, Bone and Cartilage Metabolism Research Unit, CHU Centre-Ville, Policliniques L. Brull, Quai Godefroid Kurth 45 (9ème étage), 4020 Liege, Belgium. E-mail: jyreginster@ulg.ac.be